[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
October 9, 2018

Campaign Contributions From Political Action Committees to Members of Congressional Committees Responding to the Opioid Crisis

Author Affiliations
  • 1Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia
  • 2Division of General Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia
JAMA. 2018;320(14):1489-1491. doi:10.1001/jama.2018.11338

Federal lawmakers have recently taken steps to ensure that the policy response to the opioid crisis is not influenced by advocacy groups with financial ties to the opioid industry.1,2 However, whether members of Congress might have relevant conflicts of interest stemming from financial ties to the opioid industry is unknown. Although advocacy groups can influence policy only indirectly, members of Congress oversee federal agencies and are directly responsible for crafting legislation to address the opioid crisis. In particular, members of the Senate Health, Education, Labor, and Pensions (HELP) Committee and the House Energy and Commerce Committee have led the Senate and House responses to the crisis.